Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice

被引:49
|
作者
Sun, Lei [1 ]
Yang, Xiaoxiao [2 ]
Li, Qi [1 ]
Zeng, Peng [1 ]
Liu, Ying [1 ]
Liu, Lipei [1 ]
Chen, Yuanli [2 ]
Yu, Miao [1 ]
Ma, Chuanrui [1 ]
Li, Xiaoju [1 ]
Li, Yan [1 ]
Zhang, Rongxin [3 ]
Zhu, Yan [4 ]
Miao, Qing Robert [5 ,6 ]
Han, Jihong [2 ,7 ]
Duan, Yajun [2 ,7 ]
机构
[1] Nankai Univ, Dept Biochem & Mol Biol, Coll Life Sci, Tianjin, Peoples R China
[2] Hefei Univ Technol, Coll Biomed Engn, Dept Biomed Sci, Hefei, Peoples R China
[3] Tianjin Med Univ, Dept Physiol, Tianjin, Peoples R China
[4] Tianjin Univ Tradit Chinese Med, Dept Pharmacol, Tianjin, Peoples R China
[5] Med Coll Wisconsin, Dept Surg, 8700 W Wisconsin Ave, Milwaukee, WI 53226 USA
[6] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA
[7] Nankai Univ, Dept Biochem & Mol Biol, Coll Life Sci, State Key Lab Med Chem Biol, Tianjin, Peoples R China
基金
中国国家自然科学基金; 对外科技合作项目(国际科技项目);
关键词
adiponectin; adiponectin receptors; AMP-activated protein kinases; atherosclerosis; peroxisome proliferator-activated receptors; PLASMA-PROTEIN; PPAR-GAMMA; PCSK9; CHOLESTEROL; TRANSCRIPTION; MODULATOR; LIGANDS; AGONIST; STATINS; BINDING;
D O I
10.1161/ATVBAHA.117.309630
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective-The reduced adiponectin levels are associated with atherosclerosis. Adiponectin exerts its functions by activating adiponectin receptor (AdipoR). Proprotein convertase subtilisin kexin type 9 (PCSK9) degrades LDLR protein (low-density lipoprotein receptor) to increase serum LDL-cholesterol levels. PCSK9 expression can be regulated by PPAR gamma (peroxisome proliferator-activated receptor.) or SREBP2 (sterol regulatory element-binding protein 2). The effects of AdipoR agonists on PCSK9 and LDLR expression, serum lipid profiles, and atherosclerosis remain unknown. Approach and Results-At cellular levels, AdipoR agonists (ADP355 and AdipoRon) induced PCSK9 transcription/expression that solely depended on activation of PPAR-responsive element in the PCSK9 promoter. AdipoR agonists induced PPAR gamma expression; thus, the AdipoR agonist-activated PCSK9 expression/production was impaired in PPAR gamma deficient hepatocytes. Meanwhile, AdipoR agonists transcriptionally activated LDLR expression by activating SRE in the LDLR promoter. Moreover, AMP-activated protein kinase alpha (AMPK alpha) was involved in AdipoR agonist-activated PCSK9 expression. In wild-type mice, ADP355 increased PCSK9 and LDLR expression and serum PCSK9 levels, which was associated with activation of PPAR gamma, AMPK alpha and SREBP2 and reduction of LDL-cholesterol levels. In contrast, ADP355 reduced PCSK9 expression/secretion in apoE-deficient (apoE(-/-)) mice, but it still activated hepatic LDLR, PPAR gamma, AMPK alpha, and SREBP2. More importantly, ADP355 inhibited lesions in en face aortas and sinus lesions in aortic root in apoE(-/-) mice with amelioration of lipid profiles. Conclusions-Our study demonstrates that AdipoR activation by agonists regulated PCSK9 expression differently in wildtype and apoE(-/-) mice. However, ADP355 activated hepatic LDLR expression and ameliorated lipid metabolism in both types of mice and inhibited atherosclerosis in apoE(-/-) mice. Visual Overview-An online visual overview is available for this article.
引用
收藏
页码:1290 / +
页数:22
相关论文
共 50 条
  • [31] Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Brief Overview
    Noel, Zachary R.
    Beavers, Craig J.
    AMERICAN JOURNAL OF MEDICINE, 2017, 130 (02): : 229.e1 - 229.e4
  • [32] A short review of proprotein convertase subtilisin/kexin type 9 inhibitors
    Alali, Rudaynah A.
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2019, 20 (01) : 1 - 8
  • [33] Potential of Proprotein Convertase Subtilisin/Kexin Type 9 Based Therapeutics
    Evan A. Stein
    Gary D. Swergold
    Current Atherosclerosis Reports, 2013, 15
  • [34] Proprotein convertase subtilisin/kexin type 9 and apelin in fibromyalgia syndrome
    Tas, Nevsun Pihtili
    Baykara, Rabia Aydogan
    Kamanli, Ayhan
    Gurbuz, Ali
    Cure, Erkan
    Cure, Medine Cumhur
    Erdem, Mehmet
    Yildirim, Tugce Tasar
    ARCHIVES OF RHEUMATOLOGY, 2024, 39 (03) : 375 - 383
  • [35] Proprotein convertase subtilisin/kexin type 9 in patients with systemic sclerosis
    Ferraz-Amaro, I.
    Delgado-Frias, E.
    Hernandez-Hernandez, V.
    Sanchez-Perez, H.
    de Armas-Rillo, L.
    Garcia-Dopico, J. A.
    Diaz-Gonzalez, F.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2020, 38 (03) : S18 - S24
  • [36] Advances in the field of proprotein convertase subtilisin kexin type 9 inhibitors
    Eisen, Alon
    Giugliano, Robert P.
    CURRENT OPINION IN CARDIOLOGY, 2016, 31 (06) : 644 - 653
  • [37] Regulation of proprotein convertase subtilisin/kexin type 9: Therapeutical perspectives
    Chan, Dick C.
    ATHEROSCLEROSIS, 2011, 217 (01) : 77 - 79
  • [38] PROPROTEIN CONVERTASE SUBTILISIN/ KEXIN TYPE 9 LEVELS AND ARTERIAL FUNCTION
    Koutagiar, I.
    Vlachopoulos, C.
    Terentes-Printzios, D.
    Skoumas, J.
    Skliros, N.
    Rigatou, A.
    Ioakeimidis, N.
    Pantou, S.
    Georgakopoulos, C.
    Miliou, A.
    Tousoulis, D.
    ATHEROSCLEROSIS, 2018, 275 : E132 - E132
  • [39] Proprotein Convertase Subtilisin Kexin Type 9 Null Mice Are Protected From Postprandial Triglyceridemia
    Le May, Cedric
    Kourimate, Sanae
    Langhi, Cedric
    Chetiveaux, Maud
    Jarry, Anne
    Comera, Christine
    Collet, Xavier
    Kuipers, Folkert
    Krempf, Michel
    Cariou, Bertrand
    Costet, Philippe
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2009, 29 (05) : 684 - U157
  • [40] Hypercholesterolemia,low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9
    Hong-mei Gu
    Da-wei Zhang
    TheJournalofBiomedicalResearch, 2015, 29 (05) : 356 - 361